Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Cytos Rises After Asthma Drug Succeeds in Trial: Zurich Mover

March 13 (Bloomberg) -- Cytos Biotechnology AG, a Swiss developer of an experimental drug for allergic asthma, rose to the highest in almost two months after the medicine met its main goals in a patient study.

Cytos climbed 9.7 percent to 4.29 Swiss francs in Zurich, the highest since Jan. 16, giving the Schlieren, Switzerland-based company a market value of 96.2 million francs ($101 million). Almost 280,000 shares were traded, six times the three-month daily average. The stock was the second-biggest gainer on the Swiss Performance Index.

In a trial among 63 patients in Germany, those treated with the drug, CYT003, had improved control of their asthma after treatment with inhaled corticosteroids stopped, while those who received a placebo saw their disease worsen, Cytos said in a statement today. The drug was safe and generally well-tolerated, Cytos said.

Results from a follow-up trial in 360 patients that started in the fourth quarter of last year are expected in the first half of 2014, Cytos said.

To contact the reporter on this story: Simeon Bennett in Geneva at sbennett9@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.